OptiForm® Solution Suite to Enhance Bioavailability and Accelerate Development

Article

Catalent’s Optiform® Solution Suite platform integrates four technologies to match the best drug delivery methodologies to developmental API molecules, with the goal of providing optimal animal PK prototypes in just twelve weeks.

 

 

Catalent’s new OptiForm Solution Suite combines both predictive and high throughput screening platforms - designed to identify the most stable and efficient drug form of an API - with delivery technology feasibility studies, and expert input from multi-disciplinary teams to address key developmental challenges.
 

OptiForm Solution Suite is designed to efficiently and rapidly help solve complex bioavailability challenges for early stage molecules by integrating superior expertise and know-how to match the best, most innovative, drug delivery technologies to each developmental molecule, with the goal of providing optimal animal PK materials in just twelve weeks.

 

OptiForm Solution Suite helps enable faster development with a 3-step process:

  • ASSESS: By applying proven high throughput screening tools, detailed pre-formulation data are collected to characterise the molecule's potential challenges.
     

  • ENHANCE: Formulation development and technology experts determine the feasibility of the proposed formulation approaches, recommend candidate formulations and collect preliminary stability data.
     

  • DELIVER: In twelve weeks, a dedicated advisor will provide a recommended path forward, based on rigorous data, accompanied by animal PK study materials to enter animal trials with optimised product faster.
     

Contact Details :

Catalent Pharma Solutions
Website: www.catalent.com
E-mail: solutions@catalent.com

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content